Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study

The Journal of Nervous and Mental Disease
Marvin S SwartzJeffrey A Lieberman

Abstract

This study examined baseline correlates of substance use in the NIMH Clinical Antipsychotic Trials of Intervention Effectiveness project. Approximately 60% of the sample was found to use substances, including 37% with current evidence of substance use disorders. Users (with and without substance use disorders), compared with nonusers, were significantly more likely to be male, be African-American, have lower educational attainment, have a recent period of homelessness, report more childhood conduct problems, have a history of major depression, have lower negative symptom and higher positive symptom scores on the Positive and Negative Syndrome Scale, and have a recent illness exacerbation. Individuals with comorbid substance use disorders were significantly more likely to be male, report more childhood conduct problems, have higher positive symptom scores on the Positive and Negative Syndrome Scale, and have a recent illness exacerbation. These analyses suggest that substance use disorders in schizophrenia are especially common among men with a history of childhood conduct disorder problems and that childhood conduct disorder problems are potent risk factors for substance use disorders in schizophrenia.

References

Jul 1, 1991·The Journal of Nervous and Mental Disease·A I Alterman, J S Cacciola
Sep 1, 1991·The American Journal of Psychiatry·F CournosB Agosin
Mar 1, 1991·Acta Psychiatrica Scandinavica·H J JacksonJ Edwards
Jul 1, 1990·Schizophrenia Research·D AddingtonB Schissel
Jan 1, 1990·Schizophrenia Bulletin·R E DrakeM S Beaudett
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1984·Comprehensive Psychiatry·R CadoretR Widmer
Jan 5, 1995·Forensic Science International : Synergy·R L DuPont, W A Baumgartner
May 1, 1996·Schizophrenia Research·C D SwoffordL B Inderbitzin
Mar 18, 2000·Clinical Psychology Review·J J BlanchardA R Sherwood
Feb 24, 2001·American Journal of Public Health·S D RosenbergM P Salyers
Jan 5, 2002·Journal of Traumatic Stress·L A GoodmanUNKNOWN 5 Site Health and Risk Study Research Committee
Oct 3, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Robin G McCreadie, UNKNOWN Scottish Comorbidity Study Group
May 30, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Marvin S SwartzMichael J Hannon
Jun 19, 2004·The American Journal on Addictions·Santanu GoswamiGagandeep Singh

❮ Previous
Next ❯

Citations

Jan 2, 2007·Neurotoxicity Research·John H KrystalGodfrey Pearlson
May 22, 2007·Neurotoxicity Research·Tomas PalomoRichard J Beninger
Nov 30, 2010·Community Mental Health Journal·Greg GreenbergUNKNOWN CATIE Investigators
Oct 5, 2007·Current Psychiatry Reports·Kathleen T BradyBryan K Tolliver
Dec 12, 2007·Psychological Medicine·P A RingenO A Andreassen
Aug 8, 2012·Molecular Psychiatry·J L ThompsonA Abi-Dargham
Sep 19, 2012·Clinical Neuropharmacology·Stephen Ross, Eric Peselow
Jul 26, 2013·Schizophrenia Bulletin·Amber L BahorikShaun M Eack
Aug 14, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Jeffrey W SwansonUNKNOWN CATIE investigators
Nov 26, 2010·BMC Psychiatry·Carolyn J Asher, Linda Gask
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinRaoul Belzeaux
Dec 5, 2008·Psychiatry Research·Jacopo Vittoriano BizzarriGiovanni Battista Cassano
Jun 19, 2007·Journal of Substance Abuse Treatment·Alan I GreenChristopher O'Keefe
Jan 24, 2007·Clinical Psychology Review·Lynsey GreggGillian Haddock
Oct 31, 2006·International Journal of Law and Psychiatry·Richard A Van DornSarah Mustillo
Jan 19, 2008·Addiction Biology·Elin LehrmannWilliam J Freed
Mar 1, 2012·International Journal of Methods in Psychiatric Research·Matthew M LargeOlav B Nielssen
Jul 17, 2012·Psychiatry Research·Richard A Van DornMarvin S Swartz
May 1, 2012·Neuroscience Letters·Vanessa Faria GonçalvesJames L Kennedy
Jan 17, 2012·Psychiatric Rehabilitation Journal·Ashli J SheidowMaryann Davis
Jun 26, 2007·Schizophrenia Research·Jeffrey SwansonMarvin S Swartz
Sep 15, 2010·Schizophrenia Research·Yoshihiro KinoshitaYuji Okazaki
Oct 10, 2007·Harvard Review of Psychiatry·Theo C Manschreck, Roger A Boshes
Nov 14, 2007·The Australian and New Zealand Journal of Psychiatry·Murat YücelWarrick J Brewer
Sep 11, 2007·The Australian and New Zealand Journal of Psychiatry·Stéphane PotvinEmmanuel Stip
Feb 23, 2012·European Addiction Research·Kjersti PedersenEinar Kringlen
Jun 23, 2011·Human Psychopharmacology·Maria VaresErik G Jönsson
Nov 24, 2006·Journal of Psychiatric Practice·Rajiv TandonUNKNOWN Treatment Effectiveness in Schizophrenia Consortium
Jun 20, 2008·International Journal of Clinical Practice·J Volavka, L Citrome
Nov 11, 2008·Annals of the New York Academy of Sciences·Elin Lehrmann, William J Freed
Nov 21, 2007·The British Journal of Psychiatry. Supplement·Iain KooymanElizabeth Walsh
Sep 14, 2007·European Addiction Research·Luis SanJose Martinez-Raga
Jul 31, 2013·Psychiatry and Clinical Neurosciences·Patrizia Thoma, Irene Daum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here